Table 1.
Clinical and laboratory features of Swedish patients with stage 5 CKD and control subjectsa
| Parameter | Control Subjects(n = 70) | Patients with Stage 5 CKD(n = 207) |
|---|---|---|
| Age (yr; mean ± SD) | 62 ± 11 | 53 ± 12b |
| Gender (M/F) | 48/22 | 122/85 |
| BMI (kg/m2; mean ± SD) | 26 ± 4 | 25 ± 4 |
| GFR (ml/min per 1.73 m2; mean ± SD) | 87 ± 14 | 6 ± 2b |
| Diabetes (%) | – | 30 |
| CVD (%) | – | 33 |
| MAP (mmHg) | – | 107 (64 to 147) |
| Total cholesterol (mmol/L; mean ± SD) | 5.2 ± 0.9 | 5.3 ± 1.5 |
| Triglycerides (mmol/L; median [range]) | 1.1 (0.5 to 3.5) | 1.8 (0.2 to 8.6) |
| HDL cholesterol (mmol/L; median [range]) | 1.4 (0.8 to 3.6) | 1.2 (0.1 to 7.0) |
| Serum albumin (g/dl; mean ± SD) | 3.9 ± 0.3 | 3.3 ± 0.6b |
| HbA1c (%; mean ± SD) | – | 5.4 ± 1.7 |
| Plasma insulin (μIU/ml; median [range]) | 6.3 (1.9 to 21.0) | 14.7 (3.0 to 79.0)b |
| Plasma glucose (mmol/L; mean ± SD) | – | 6.4 ± 3.9 |
| UAE (mg/24-h; median [range]) | – | 1913 (13 to 11808) |
| hsCRP (mg/L; median [range]) | 1.2 (0.2 to 32.0) | 4.3 (0.2 to 218.0)b |
| PTX3 (ng/ml; median [range]) | 1.8 (0.1 to 9.2) | 5.3 (1.0 to 58.0)b |
| VCAM-1 (ng/ml; median [range]) | 689 (402 to 1290) | 1323 (546 to 4085)b |
a
BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; HbA1c, glycosylated hemoglobin; hsCRP, high-sensitivity C-reactive protein; MAP, mean arterial BP; PTX3, pentraxin 3; UAE, urinary albumin excretion; VCAM-1, vascular cellular adhesion molecule-1.
b
Significant difference P < 0.001.